{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:51:14Z","timestamp":1794585074503,"version":"4.9.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:00:00Z","timestamp":1602115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:00:00Z","timestamp":1602115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"US National Institute of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Identifying factors underlying resistance to immune checkpoint therapy (ICT) is still challenging. Most cancer patients do not respond to ICT and the availability of the predictive biomarkers is limited. Here, we re-analyze a publicly available single-cell RNA sequencing (scRNA-seq) dataset of melanoma samples of patients subjected to ICT and identify a subset of macrophages overexpressing TREM2 and a subset of gammadelta T cells that are both overrepresented in the non-responding tumors. In addition, the percentage of a B cell subset is significantly lower in the non-responders. The presence of these immune cell subtypes is corroborated in other publicly available scRNA-seq datasets. The analyses of bulk RNA-seq datasets of the melanoma samples identify and validate a signature - ImmuneCells.Sig - enriched with the genes characteristic of the above immune cell subsets to predict response to immunotherapy. ImmuneCells.Sig could represent a valuable tool for clinical decision making in patients receiving immunotherapy.<\/jats:p>","DOI":"10.1038\/s41467-020-18546-x","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T06:03:22Z","timestamp":1602137002000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":178,"title":["A gene expression signature of TREM2hi macrophages and \u03b3\u03b4 T cells predicts immunotherapy response"],"prefix":"10.1038","volume":"11","author":[{"given":"Donghai","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,8]]},"reference":[{"key":"18546_CR1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"New Engl. J. Med."},{"key":"18546_CR2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"18546_CR3","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568\u2013571 (2014).","journal-title":"Nature"},{"key":"18546_CR4","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-01062-w","volume":"8","author":"M Sade-Feldman","year":"2017","unstructured":"Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8, 1136 (2017).","journal-title":"Nat. Commun."},{"key":"18546_CR5","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","volume":"167","author":"J Gao","year":"2016","unstructured":"Gao, J. et al. Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167, 397\u2013404.e399 (2016).","journal-title":"Cell"},{"key":"18546_CR6","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998\u20131013.e1020 (2018).","journal-title":"Cell"},{"key":"18546_CR7","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","volume":"175","author":"L Jerby-Arnon","year":"2018","unstructured":"Jerby-Arnon, L. et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell 175, 984\u2013997 e924 (2018).","journal-title":"Cell"},{"key":"18546_CR8","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251\u20131259 (2019).","journal-title":"Nat. Med."},{"key":"18546_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35\u201344 (2016).","journal-title":"Cell"},{"key":"18546_CR10","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934\u2013949.e915 (2017).","journal-title":"Cell"},{"key":"18546_CR11","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide, T. N. et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy. Cancer Cell 35, 238\u2013255 e236 (2019).","journal-title":"Cancer Cell"},{"key":"18546_CR12","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","volume":"25","author":"D Liu","year":"2019","unstructured":"Liu, D. et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat. Med. 25, 1916\u20131927 (2019).","journal-title":"Nat. Med."},{"key":"18546_CR13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"18546_CR14","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u20131902.e1821 (2019).","journal-title":"Cell"},{"key":"18546_CR15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"18546_CR16","doi-asserted-by":"crossref","unstructured":"Becht, E. et al. Dimensionality reduction for visualizing single-cell data using UMAP. Nat. Biotechnol. 37, 38\u201344 (2019).","DOI":"10.1038\/nbt.4314"},{"key":"18546_CR17","doi-asserted-by":"crossref","first-page":"11906","DOI":"10.1073\/pnas.1818488116","volume":"116","author":"G Pizzolato","year":"2019","unstructured":"Pizzolato, G. et al. Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVdelta1 and TCRVdelta2 gammadelta T lymphocytes. Proc. Natl Acad. Sci. USA 116, 11906\u201311915 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"18546_CR18","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1093\/nar\/gkz601","volume":"47","author":"F Pont","year":"2019","unstructured":"Pont, F., Tosolini, M. & Fournie, J. J. Single-Cell Signature Explorer for comprehensive visualization of single cell signatures across scRNA-seq datasets. Nucleic Acids Res. 47, e133 (2019).","journal-title":"Nucleic Acids Res."},{"key":"18546_CR19","unstructured":"Butte, A. J. et al. Determining significant fold differences in gene expression analysis. Pac. Symp. Biocomput. 6, 6\u201317 (2001)."},{"key":"18546_CR20","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.cell.2018.09.030","volume":"175","author":"MM Gubin","year":"2018","unstructured":"Gubin, M. M. et al. High-dimensional analysis delineates myeloid and lymphoid compartment remodeling during successful immune-checkpoint cancer therapy. Cell 175, 1014\u20131030.e1019 (2018).","journal-title":"Cell"},{"key":"18546_CR21","doi-asserted-by":"crossref","first-page":"D377","DOI":"10.1093\/nar\/gks1118","volume":"41","author":"H Mi","year":"2013","unstructured":"Mi, H., Muruganujan, A. & Thomas, P. D. PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res. 41, D377\u2013D386 (2013).","journal-title":"Nucleic Acids Res."},{"key":"18546_CR22","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"18546_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v059.i01","volume":"59","author":"J Budczies","year":"2014","unstructured":"Budczies, J. et al. cancerclass: an R Package for development and validation of diagnostic tests from high-dimensional molecular data. J. Stat. Softw. 59, 1\u201319 (2014).","journal-title":"J. Stat. Softw."},{"key":"18546_CR24","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"18546_CR25","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang, P. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med. 24, 1550\u20131558 (2018).","journal-title":"Nat. Med."},{"key":"18546_CR26","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.cell.2018.03.026","volume":"173","author":"SA Shukla","year":"2018","unstructured":"Shukla, S. A. et al. Cancer-germline antigen expression discriminates clinical outcome to CTLA-4 blockade. Cell 173, 624\u2013633.e628 (2018).","journal-title":"Cell"},{"key":"18546_CR27","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/s41591-018-0157-9","volume":"24","author":"N Auslander","year":"2018","unstructured":"Auslander, N. et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat. Med. 24, 1545\u20131549 (2018).","journal-title":"Nat. Med."},{"key":"18546_CR28","doi-asserted-by":"crossref","first-page":"e1659094","DOI":"10.1080\/2162402X.2019.1659094","volume":"8","author":"S Yang","year":"2019","unstructured":"Yang, S. et al. Identification of a prognostic immune signature for cervical cancer to predict survival and response to immune checkpoint inhibitors. Oncoimmunology 8, e1659094 (2019).","journal-title":"Oncoimmunology"},{"key":"18546_CR29","doi-asserted-by":"crossref","unstructured":"Dominguez, C. X. et al. Single-cell RNA sequencing reveals stromal evolution into LRRC15+ myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Discov. 10, CD-19-0644 (2019).","DOI":"10.1158\/2159-8290.CD-19-0644"},{"key":"18546_CR30","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","volume":"25","author":"AC Huang","year":"2019","unstructured":"Huang, A. C. et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat. Med. 25, 454\u2013461 (2019).","journal-title":"Nat. Med."},{"key":"18546_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2019.10.012","volume":"139","author":"JC Thompson","year":"2020","unstructured":"Thompson, J. C. et al. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy. Lung Cancer 139, 1\u20138 (2020).","journal-title":"Lung Cancer"},{"key":"18546_CR32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s40425-017-0272-z","volume":"5","author":"P Friedlander","year":"2017","unstructured":"Friedlander, P. et al. Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab. J. Immunother. Cancer 5, 67 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"18546_CR33","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s12282-015-0654-3","volume":"23","author":"T Imamura","year":"2016","unstructured":"Imamura, T. et al. Influence of the C5a-C5a receptor system on breast cancer progression and patient prognosis. Breast Cancer 23, 876\u2013885 (2016).","journal-title":"Breast Cancer"},{"key":"18546_CR34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.lungcan.2013.04.020","volume":"81","author":"J Gu","year":"2013","unstructured":"Gu, J. et al. Overexpression of CD88 predicts poor prognosis in non-small-cell lung cancer. Lung Cancer 81, 259\u2013265 (2013).","journal-title":"Lung Cancer"},{"key":"18546_CR35","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10346","volume":"7","author":"R Bulla","year":"2016","unstructured":"Bulla, R. et al. C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. Nat. Commun. 7, 10346 (2016).","journal-title":"Nat. Commun."},{"key":"18546_CR36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.semcdb.2017.11.023","volume":"85","author":"D Ajona","year":"2019","unstructured":"Ajona, D., Ortiz-Espinosa, S. & Pio, R. Complement anaphylatoxins C3a and C5a: Emerging roles in cancer progression and treatment. Semin. Cell Dev. Biol. 85, 153\u2013163 (2019).","journal-title":"Semin. Cell Dev. Biol."},{"key":"18546_CR37","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1158\/2326-6066.CIR-18-0891","volume":"7","author":"LT Roumenina","year":"2019","unstructured":"Roumenina, L. T. et al. Tumor cells hijack macrophage-produced complement C1q to promote tumor growth. Cancer Immunol. Res. 7, 1091\u20131105 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"18546_CR38","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1172\/JCI90962","volume":"127","author":"V Afshar-Kharghan","year":"2017","unstructured":"Afshar-Kharghan, V. The role of the complement system in cancer. J. Clin. Invest. 127, 780\u2013789 (2017).","journal-title":"J. Clin. Invest."},{"key":"18546_CR39","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3389\/fimmu.2019.00774","volume":"10","author":"R Pio","year":"2019","unstructured":"Pio, R., Ajona, D., Ortiz-Espinosa, S., Mantovani, A. & Lambris, J. D. Complementing the cancer-immunity cycle. Front. Immunol. 10, 774 (2019).","journal-title":"Front. Immunol."},{"key":"18546_CR40","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/ni967","volume":"4","author":"WK Suh","year":"2003","unstructured":"Suh, W. K. et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat. Immunol. 4, 899\u2013906 (2003).","journal-title":"Nat. Immunol."},{"key":"18546_CR41","doi-asserted-by":"crossref","first-page":"683875","DOI":"10.1155\/2010\/683875","volume":"2010","author":"M Loos","year":"2010","unstructured":"Loos, M., Hedderich, D. M., Friess, H. & Kleeff, J. B7-h3 and its role in antitumor immunity. Clin. Dev. Immunol. 2010, 683875 (2010).","journal-title":"Clin. Dev. Immunol."},{"key":"18546_CR42","first-page":"13987","volume":"8","author":"Y Jin","year":"2015","unstructured":"Jin, Y. et al. B7-H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer. Int. J. Clin. Exp. Pathol. 8, 13987\u201313995 (2015).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"18546_CR43","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1097\/SLA.0b013e3181f1939d","volume":"252","author":"T Arigami","year":"2010","unstructured":"Arigami, T. et al. B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann. Surg. 252, 1044\u20131051 (2010).","journal-title":"Ann. Surg."},{"key":"18546_CR44","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.2147\/CMAR.S209205","volume":"11","author":"K Inamura","year":"2019","unstructured":"Inamura, K. et al. Relationship of B7-H3 expression in tumor cells and tumor vasculature with FOXP3+ regulatory T cells in renal cell carcinoma. Cancer Manag. Res. 11, 7021\u20137030 (2019).","journal-title":"Cancer Manag. Res."},{"key":"18546_CR45","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","volume":"441","author":"E Bettelli","year":"2006","unstructured":"Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235\u2013238 (2006).","journal-title":"Nature"},{"key":"18546_CR46","doi-asserted-by":"crossref","first-page":"19458","DOI":"10.1073\/pnas.0709802104","volume":"104","author":"X Zang","year":"2007","unstructured":"Zang, X. et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc. Natl Acad. Sci. USA 104, 19458\u201319463 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"18546_CR47","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1302\/0301-620X.92B3.22331","volume":"92","author":"GL Cribb","year":"2010","unstructured":"Cribb, G. L., Loo, S. C. & Dickinson, I. Limb salvage for soft-tissue sarcomas of the foot and ankle. J. Bone Joint Surg. Br. 92, 424\u2013429 (2010).","journal-title":"J. Bone Joint Surg. Br."},{"key":"18546_CR48","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069\u20131086 (2018).","journal-title":"Cancer Discov."},{"key":"18546_CR49","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00262-018-2263-4","volume":"68","author":"D Umezu","year":"2019","unstructured":"Umezu, D. et al. Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment. Cancer Immunol. Immunother. 68, 201\u2013211 (2019).","journal-title":"Cancer Immunol. Immunother."},{"key":"18546_CR50","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.cell.2018.05.060","volume":"174","author":"E Azizi","year":"2018","unstructured":"Azizi, E. et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 174, 1293\u20131308 e1236 (2018).","journal-title":"Cell"},{"key":"18546_CR51","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.cell.2019.03.005","volume":"177","author":"J Wagner","year":"2019","unstructured":"Wagner, J. et al. A single-cell atlas of the tumor and immune ecosystem of human breast cancer. Cell 177, 1330\u20131345 e1318 (2019).","journal-title":"Cell"},{"key":"18546_CR52","doi-asserted-by":"crossref","unstructured":"Mould, K. J., Jackson, N. D., Henson, P. M., Seibold, M. & Janssen, W. J. Single cell RNA sequencing identifies unique inflammatory airspace macrophage subsets. JCI Insight 4, e126556 (2019).","DOI":"10.1172\/jci.insight.126556"},{"key":"18546_CR53","volume":"16","author":"Y Zhao","year":"2018","unstructured":"Zhao, Y., Niu, C. & Cui, J. Gamma-delta (gammadelta) T cells: friend or foe in cancer development? J. Transl. Med. 16, 3 (2018).","journal-title":"J. Transl. Med."},{"key":"18546_CR54","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1158\/1078-0432.CCR-18-4046","volume":"25","author":"YZ Mazzu","year":"2019","unstructured":"Mazzu, Y. Z. et al. A novel mechanism driving poor-prognosis prostate cancer: overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2 (RRM2). Clin. Cancer Res. 25, 4480\u20134492 (2019).","journal-title":"Clin. Cancer Res."},{"key":"18546_CR55","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/s13046-019-1362-1","volume":"38","author":"F Li","year":"2019","unstructured":"Li, F., Aljahdali, I. & Ling, X. Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study? J. Exp. Clin. Cancer Res. 38, 368 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"18546_CR56","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.gene.2018.07.017","volume":"675","author":"J Zhou","year":"2018","unstructured":"Zhou, J. et al. SPC24 Regulates breast cancer progression by PI3K\/AKT signaling. Gene 675, 272\u2013277 (2018).","journal-title":"Gene"},{"key":"18546_CR57","doi-asserted-by":"crossref","first-page":"21884","DOI":"10.18632\/oncotarget.15670","volume":"8","author":"H Yin","year":"2017","unstructured":"Yin, H., Meng, T., Zhou, L., Chen, H. & Song, D. SPC24 is critical for anaplastic thyroid cancer progression. Oncotarget 8, 21884\u201321891 (2017).","journal-title":"Oncotarget"},{"key":"18546_CR58","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.7150\/jca.32731","volume":"10","author":"G Liu","year":"2019","unstructured":"Liu, G., Zhao, J., Pan, B., Ma, G. & Liu, L. UBE2C overexpression in melanoma and its essential role in G2\/M transition. J. Cancer 10, 2176\u20132184 (2019).","journal-title":"J. Cancer"},{"key":"18546_CR59","volume":"17","author":"CH Mo","year":"2017","unstructured":"Mo, C. H. et al. The clinicopathological significance of UBE2C in breast cancer: a study based on immunohistochemistry, microarray and RNA-sequencing data. Cancer Cell Int. 17, 83 (2017).","journal-title":"Cancer Cell Int."},{"key":"18546_CR60","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ebiom.2019.07.030","volume":"46","author":"J Xu","year":"2019","unstructured":"Xu, J. et al. Systematic cancer-testis gene expression analysis identified CDCA5 as a potential therapeutic target in esophageal squamous cell carcinoma. EBioMedicine 46, 54\u201365 (2019).","journal-title":"EBioMedicine"},{"key":"18546_CR61","doi-asserted-by":"crossref","first-page":"1550618","DOI":"10.1080\/2162402X.2018.1550618","volume":"8","author":"T Hoeres","year":"2019","unstructured":"Hoeres, T., Holzmann, E., Smetak, M., Birkmann, J. & Wilhelm, M. PD-1 signaling modulates interferon-gamma production by Gamma Delta (gammadelta) T-Cells in response to leukemia. Oncoimmunology 8, 1550618 (2019).","journal-title":"Oncoimmunology"},{"key":"18546_CR62","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000496166","volume":"46","author":"K Wennhold","year":"2019","unstructured":"Wennhold, K., Shimabukuro-Vornhagen, A. & von Bergwelt-Baildon, M. B cell-based cancer immunotherapy. Transfus. Med. Hemother. 46, 36\u201346 (2019).","journal-title":"Transfus. Med. Hemother."},{"key":"18546_CR63","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"18546_CR64","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1158\/1078-0432.CCR-17-0270","volume":"23","author":"ML Ascierto","year":"2017","unstructured":"Ascierto, M. L. et al. Transcriptional mechanisms of resistance to anti-PD-1 therapy. Clin. Cancer Res. 23, 3168\u20133180 (2017).","journal-title":"Clin. Cancer Res."},{"key":"18546_CR65","volume":"10","author":"B Langmead","year":"2009","unstructured":"Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).","journal-title":"Genome Biol."},{"key":"18546_CR66","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/bioinformatics\/btp120","volume":"25","author":"C Trapnell","year":"2009","unstructured":"Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105\u20131111 (2009).","journal-title":"Bioinformatics"},{"key":"18546_CR67","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1186\/s12859-018-2486-6","volume":"19","author":"SX Ge","year":"2018","unstructured":"Ge, S. X., Son, E. W. & Yao, R. iDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data. BMC Bioinform. 19, 534 (2018).","journal-title":"BMC Bioinform"},{"key":"18546_CR68","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol"},{"key":"18546_CR69","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinforma. 14, 7 (2013).","journal-title":"BMC Bioinforma."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18546-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18546-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18546-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T20:13:50Z","timestamp":1670271230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18546-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,8]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["18546"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-18546-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,8]]},"assertion":[{"value":"19 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.Y. is a co-founder of OncoImmune, Inc.\u00a0All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5084"}}